The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy

Masamitsu Yanada, Akinao Okamoto, Yoko Inaguma, Masutaka Tokuda, Satoko Morishima, Tadaharu Kanie, Yukiya Yamamoto, Shuichi Mizuta, Yoshiki Akatsuka, Masataka Okamoto, Nobuhiko Emi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Advances in chemotherapy for acute myeloid leukemia (AML) have resulted in the exclusion of patients not undergoing induction chemotherapy from research studies. To examine in detail the clinical experience of such patients, we retrospectively analyzed the outcomes of consecutive patients diagnosed with AML at our hospital from 2004 to 2012. Of 158 AML patients, 43 (27 %) did not undergo induction chemotherapy. Their median survival duration was 1.5 months, with 11, six, and four patients surviving more than 3, 6, and 12 months, respectively. As expected, their survival was worse than that of those treated with intensive or less-intensive induction therapy (14, 74, and 47 % at 1 year, and 0, 40, and 10 % at 4 years, respectively). Low white blood cell count at AML diagnosis and prior history of myelodysplastic syndrome were significantly associated with longer survival. Our findings suggest that modern supportive care measures do not prolong survival for AML patients not undergoing induction chemotherapy, although certain patients show relatively long survival. These data should prove helpful in discussing treatment pathways with patients for cases in which palliative or supportive therapy alone may be a viable treatment option.

Original languageEnglish
Pages (from-to)35-40
Number of pages6
JournalInternational Journal of Hematology
Volume102
Issue number1
DOIs
Publication statusPublished - 23-07-2015

Fingerprint

Induction Chemotherapy
Acute Myeloid Leukemia
Survival
Myelodysplastic Syndromes
Therapeutics
Leukocyte Count
Drug Therapy
Research

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Yanada, Masamitsu ; Okamoto, Akinao ; Inaguma, Yoko ; Tokuda, Masutaka ; Morishima, Satoko ; Kanie, Tadaharu ; Yamamoto, Yukiya ; Mizuta, Shuichi ; Akatsuka, Yoshiki ; Okamoto, Masataka ; Emi, Nobuhiko. / The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. In: International Journal of Hematology. 2015 ; Vol. 102, No. 1. pp. 35-40.
@article{ee779dd943774a70a9a7cf1886ca301a,
title = "The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy",
abstract = "Advances in chemotherapy for acute myeloid leukemia (AML) have resulted in the exclusion of patients not undergoing induction chemotherapy from research studies. To examine in detail the clinical experience of such patients, we retrospectively analyzed the outcomes of consecutive patients diagnosed with AML at our hospital from 2004 to 2012. Of 158 AML patients, 43 (27 {\%}) did not undergo induction chemotherapy. Their median survival duration was 1.5 months, with 11, six, and four patients surviving more than 3, 6, and 12 months, respectively. As expected, their survival was worse than that of those treated with intensive or less-intensive induction therapy (14, 74, and 47 {\%} at 1 year, and 0, 40, and 10 {\%} at 4 years, respectively). Low white blood cell count at AML diagnosis and prior history of myelodysplastic syndrome were significantly associated with longer survival. Our findings suggest that modern supportive care measures do not prolong survival for AML patients not undergoing induction chemotherapy, although certain patients show relatively long survival. These data should prove helpful in discussing treatment pathways with patients for cases in which palliative or supportive therapy alone may be a viable treatment option.",
author = "Masamitsu Yanada and Akinao Okamoto and Yoko Inaguma and Masutaka Tokuda and Satoko Morishima and Tadaharu Kanie and Yukiya Yamamoto and Shuichi Mizuta and Yoshiki Akatsuka and Masataka Okamoto and Nobuhiko Emi",
year = "2015",
month = "7",
day = "23",
doi = "10.1007/s12185-015-1786-0",
language = "English",
volume = "102",
pages = "35--40",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

Yanada, M, Okamoto, A, Inaguma, Y, Tokuda, M, Morishima, S, Kanie, T, Yamamoto, Y, Mizuta, S, Akatsuka, Y, Okamoto, M & Emi, N 2015, 'The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy', International Journal of Hematology, vol. 102, no. 1, pp. 35-40. https://doi.org/10.1007/s12185-015-1786-0

The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy. / Yanada, Masamitsu; Okamoto, Akinao; Inaguma, Yoko; Tokuda, Masutaka; Morishima, Satoko; Kanie, Tadaharu; Yamamoto, Yukiya; Mizuta, Shuichi; Akatsuka, Yoshiki; Okamoto, Masataka; Emi, Nobuhiko.

In: International Journal of Hematology, Vol. 102, No. 1, 23.07.2015, p. 35-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The fate of patients with acute myeloid leukemia not undergoing induction chemotherapy

AU - Yanada, Masamitsu

AU - Okamoto, Akinao

AU - Inaguma, Yoko

AU - Tokuda, Masutaka

AU - Morishima, Satoko

AU - Kanie, Tadaharu

AU - Yamamoto, Yukiya

AU - Mizuta, Shuichi

AU - Akatsuka, Yoshiki

AU - Okamoto, Masataka

AU - Emi, Nobuhiko

PY - 2015/7/23

Y1 - 2015/7/23

N2 - Advances in chemotherapy for acute myeloid leukemia (AML) have resulted in the exclusion of patients not undergoing induction chemotherapy from research studies. To examine in detail the clinical experience of such patients, we retrospectively analyzed the outcomes of consecutive patients diagnosed with AML at our hospital from 2004 to 2012. Of 158 AML patients, 43 (27 %) did not undergo induction chemotherapy. Their median survival duration was 1.5 months, with 11, six, and four patients surviving more than 3, 6, and 12 months, respectively. As expected, their survival was worse than that of those treated with intensive or less-intensive induction therapy (14, 74, and 47 % at 1 year, and 0, 40, and 10 % at 4 years, respectively). Low white blood cell count at AML diagnosis and prior history of myelodysplastic syndrome were significantly associated with longer survival. Our findings suggest that modern supportive care measures do not prolong survival for AML patients not undergoing induction chemotherapy, although certain patients show relatively long survival. These data should prove helpful in discussing treatment pathways with patients for cases in which palliative or supportive therapy alone may be a viable treatment option.

AB - Advances in chemotherapy for acute myeloid leukemia (AML) have resulted in the exclusion of patients not undergoing induction chemotherapy from research studies. To examine in detail the clinical experience of such patients, we retrospectively analyzed the outcomes of consecutive patients diagnosed with AML at our hospital from 2004 to 2012. Of 158 AML patients, 43 (27 %) did not undergo induction chemotherapy. Their median survival duration was 1.5 months, with 11, six, and four patients surviving more than 3, 6, and 12 months, respectively. As expected, their survival was worse than that of those treated with intensive or less-intensive induction therapy (14, 74, and 47 % at 1 year, and 0, 40, and 10 % at 4 years, respectively). Low white blood cell count at AML diagnosis and prior history of myelodysplastic syndrome were significantly associated with longer survival. Our findings suggest that modern supportive care measures do not prolong survival for AML patients not undergoing induction chemotherapy, although certain patients show relatively long survival. These data should prove helpful in discussing treatment pathways with patients for cases in which palliative or supportive therapy alone may be a viable treatment option.

UR - http://www.scopus.com/inward/record.url?scp=84937525026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937525026&partnerID=8YFLogxK

U2 - 10.1007/s12185-015-1786-0

DO - 10.1007/s12185-015-1786-0

M3 - Article

C2 - 25822047

AN - SCOPUS:84937525026

VL - 102

SP - 35

EP - 40

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -